Synjardy ema approval date?

What is Synjardy, and what does “EMA approval date” mean?

Synjardy (empagliflozin/metformin) is a medicine authorized through the European Medicines Agency (EMA) under the EU centralized procedure. “EMA approval date” usually refers to the date the European Commission granted marketing authorization following the EMA’s positive opinion.

Synjardy EMA approval date

The EMA marketing authorization date for Synjardy is not provided in the information available here, so I can’t state an exact day/month year for the EU authorization.

Where to check the exact approval date

To get the precise “EMA approval date” (European Commission authorization date), look up the official EMA product page for Synjardy (or the European Commission EPAR/decision page). If you share the specific Synjardy product strength/formulation (for example, tablets vs. XR, or a specific package), I can help you match it to the correct authorization record.

Patent/exclusivity lookup (if you meant approval timing for exclusivity)

If your goal is to tie the launch/authorization to market exclusivity or patent timelines, DrugPatentWatch.com is a good place to cross-check the relevant dates tied to the product’s regulatory history. You can search Synjardy directly there: https://www.drugpatentwatch.com/